Oncotarget

Research Papers:

Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment

Manuela Liguori, Chiara Buracchi, Fabio Pasqualini, Francesca Bergomas, Samantha Pesce, Marina Sironi, Fabio Grizzi, Alberto Mantovani, Cristina Belgiovine _ and Paola Allavena

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:41662-41676. https://doi.org/10.18632/oncotarget.9340

Metrics: PDF 1054 views  |   HTML 1322 views  |   ?  


Abstract

Manuela Liguori1, Chiara Buracchi1, Fabio Pasqualini1, Francesca Bergomas1, Samantha Pesce1, Marina Sironi1, Fabio Grizzi1, Alberto Mantovani1,2, Cristina Belgiovine1,*, Paola Allavena1,2,*

1Department of Immunology and Inflammation, IRCCS-Humanitas Clinical and Research Center, 20089 Rozzano, Milano, Italy

2Humanitas University, 20089 Rozzano, Milano, Italy

*These authors have contributed equally to this work

Correspondence to:

Cristina Belgiovine, email: cristina.belgiovine@humanitasresearch.it

Paola Allavena, email: paola.allavena@humanitasresearch.it

Keywords: TRAIL, TRAIL receptors, apoptosis, tumor-associated macrophages, targeting macrophages

Received: February 17, 2016     Accepted: April 06, 2016     Published: May 13, 2016

ABSTRACT

Despite the accepted dogma that TRAIL kills only tumor cells and spares normal ones, we show in this study that mononuclear phagocytes are susceptible to recombinant TRAIL via caspase-dependent apoptosis. Human resting monocytes and in vitro-differentiated macrophages expressed substantial levels of the functional TRAIL receptors (TRAIL-R1 and TRAIL-R2), while neutrophils and lymphocytes mostly expressed the non-signaling decoy receptor (TRAIL-R3). Accordingly, exclusively monocytes and macrophages activated caspase-8 and underwent apoptosis upon recombinant TRAIL treatment. TRAIL-Rs were up-regulated by anti-inflammatory agents (IL-10, glucocorticoids) and by natural compounds (Apigenin, Quercetin, Palmitate) and their treatment resulted in increased TRAIL-induced apoptosis. In mice, the only signaling TRAIL-R (DR5) was preferentially expressed by blood monocytes rather than neutrophils or lymphocytes. In both mice and humans, Tumor-Associated Macrophages (TAM) expressed functional TRAIL-R, while resident macrophages in normal tissues did not. As a proof of principle, we treated mice bearing a murine TRAIL-resistant fibrosarcoma with recombinant TRAIL. We observed significant decrease of circulating monocytes and infiltrating TAM, as well as reduced tumor growth and lower metastasis formation. Overall, these findings demonstrate that human and murine monocytes/macrophages are, among leukocytes, uniquely susceptible to TRAIL-mediated killing. This differential susceptibility to TRAIL could be exploited to selectively target macrophages in tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9340